Today we see more antibiotics in hospitals, clinics, pharmaceutical companies, and even in the houses of people. Scientists and experts are scared that an era will soon arrive where we won’t be able to perform invasive treatments and surgeries and people would die routinely from simple bacterial infections due to antibiotic-resistant bacteria in populations. Already we are seeing strains of antibiotic-resistance bacteria in both hospital and community settings.

For the past few years, we have been using antibiotics so much that now it increases the chances for bacteria to develop resistance against them. This could create a range of antibiotic-resistant bacteria surfacing in the future which would reduce our ability to fight normal bacterial fungal infections.

The Center For Disease Dynamics, Economics & Policy (CDDEP) suggests that multiple strategies can be implemented simultaneously to better communicate the antibiotic resistance problem. These methods include vaccination to avoid disease and minimize antibiotic demand, proactive hospital infection management, judicious antibiotic prescribing and cycling, narrow-spectrum antibiotic care, creation of new antibiotics, AMR communication methods and co-ordinated federal policies to guide this tool. 

CDDEP has developed the Drug Resistance Index (DRI) program which delivers a country-by-country overview of antibiotic therapy effectiveness. CDDEP ‘s Global Partnership for Antibiotic Resistance is creating implementable policy strategies for India, Kenya, South Africa, and Vietnam. Researchers find gaps in how antibiotics are produced and controlled, and how the use and resistance of antibiotics are monitored. The expert program developed in these five countries will be at the heart of a broader partnership that will help policy-makers in other low- and middle-income countries to control antibiotic resistance and study antibiotic-resistant bacteria as part of a global effort.